Sign In
Buy CPIX
$5.77
+0.0700 (+1.23%)
At Close: Jun 02, 2026
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
04:05pm, Tuesday, 29'th Apr 2025
NASHVILLE, Tenn. , April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financ
FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
04:05pm, Wednesday, 19'th Mar 2025
Ifetroban demonstrated significant 5.4% improvement in cardiac function NASHVILLE, Tenn. , March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical co
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript
07:14pm, Tuesday, 04'th Mar 2025
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Molly Aggas – Account Supervisor-Dalton Agency A.J. Kazimi – Chief Exe
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
04:05pm, Tuesday, 04'th Mar 2025
2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval NASHV
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
04:05pm, Tuesday, 25'th Feb 2025
NASHVILLE, Tenn. , Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial res
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
07:30am, Tuesday, 18'th Feb 2025
Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world's second-largest market NASHVILLE, Tenn. and SHANGHAI , Feb. 18, 202
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease
01:31pm, Tuesday, 04'th Feb 2025
On Tuesday, Cumberland Pharmaceuticals Inc. CPIX released topline results from its Phase 2 FIGHT DMD trial.
NASHVILLE, Tenn. , Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases,
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
12:08pm, Tuesday, 10'th Dec 2024
On Monday, the FDA approved Cumberland Pharmaceuticals Inc's CPIX supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product.
FDA APPROVES ACETADOTE® sNDA
04:05pm, Monday, 09'th Dec 2024
- New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn. , Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on deliv
Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript
01:17pm, Saturday, 09'th Nov 2024
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Exe
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
04:05pm, Thursday, 07'th Nov 2024
– New Real World Study of 150,000 Patients Favors Caldolor over ketorolac – – DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations – N
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
05:21pm, Wednesday, 06'th Nov 2024
NASHVILLE, Tenn. , Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administ
New Study Compares Caldolor® (ibuprofen injection) to ketorolac
04:05pm, Tuesday, 05'th Nov 2024
– Real World Study Compared Over 150,000 Adult & Pediatric Patients – – Caldolor Associated with Fewer Adverse Drug Reactions – – Caldolor also Impr
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
04:05pm, Thursday, 31'st Oct 2024
NASHVILLE, Tenn. , Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financ
